Total Payments
$2,271
2024 Payments
$394.12
Companies
11
Transactions
69
Medicare Patients
1,520
Medicare Billing
$128,361
Payment Breakdown by Category
Food & Beverage$2,271 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,271 | 69 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $864.03 | 39 | $0 (2024) |
| Novo Nordisk Inc | $755.81 | 14 | $0 (2023) |
| Amgen Inc. | $388.72 | 5 | $0 (2024) |
| Lilly USA, LLC | $136.14 | 3 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $39.82 | 2 | $0 (2017) |
| Astellas Pharma US Inc | $16.88 | 1 | $0 (2023) |
| VIVUS, Inc. | $15.39 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $13.86 | 1 | $0 (2019) |
| GlaxoSmithKline, LLC. | $13.76 | 1 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $13.72 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $394.12 | 5 | Amgen Inc. ($249.98) |
| 2023 | $294.60 | 15 | ABBVIE INC. ($177.03) |
| 2022 | $958.14 | 29 | ABBVIE INC. ($397.27) |
| 2021 | $475.93 | 11 | Novo Nordisk Inc ($350.91) |
| 2019 | $13.86 | 1 | Merck Sharp & Dohme Corporation ($13.86) |
| 2017 | $134.66 | 8 | Boehringer Ingelheim Pharmaceuticals, Inc. ($39.82) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/03/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $4.74 | General |
| Category: NEUROSCIENCE | ||||||
| 06/28/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: NEUROSCIENCE | ||||||
| 06/27/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Inflammation | ||||||
| 04/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Cardiology | ||||||
| 02/20/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $120.45 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $123.65 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Diabetes | ||||||
| 07/25/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $6.19 | General |
| Category: NEUROSCIENCE | ||||||
| 06/01/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.69 | General |
| Category: NEUROSCIENCE | ||||||
| 05/12/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: RESPIRATORY | ||||||
| 05/03/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Diabetes | ||||||
| 04/06/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.69 | General |
| Category: NEUROSCIENCE | ||||||
| 03/15/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: NEUROSCIENCE | ||||||
| 02/22/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.38 | General |
| Category: NEUROSCIENCE | ||||||
| 02/09/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: Diabetes | ||||||
| 02/08/2023 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Urology | ||||||
| 01/18/2023 | Teva Pharmaceuticals USA, Inc. | AirDuo Digihaler (Drug) | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: Respiratory | ||||||
| 01/11/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/04/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Diabetes | ||||||
| 12/12/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.67 | General |
| Category: Diabetes | ||||||
| 12/08/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $5.80 | General |
| Category: NEUROSCIENCE | ||||||
| 11/28/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $5.90 | General |
| Category: NEUROSCIENCE | ||||||
| 11/11/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $12.62 | General |
| Category: NEUROSCIENCE | ||||||
| 11/09/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 410 | 560 | $135,760 | $32,499 |
| 2022 | 9 | 437 | 604 | $121,476 | $34,174 |
| 2021 | 8 | 359 | 538 | $80,160 | $31,616 |
| 2020 | 7 | 314 | 449 | $62,195 | $30,071 |
Total Patients
1,520
Total Services
2,151
Medicare Billing
$128,361
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 149 | 289 | $79,475 | $14,232 | 17.9% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 24 | 24 | $15,840 | $6,726 | 42.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 83 | 83 | $23,240 | $4,013 | 17.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 48 | 50 | $6,750 | $3,586 | 53.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 54 | 56 | $3,080 | $1,841 | 59.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 31 | $5,890 | $1,214 | 20.6% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 27 | 27 | $1,485 | $887.49 | 59.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 150 | 305 | $68,275 | $14,895 | 21.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 26 | 26 | $16,740 | $7,252 | 43.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 66 | 66 | $15,296 | $3,331 | 21.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 43 | 44 | $5,875 | $2,944 | 50.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 53 | 55 | $2,995 | $1,756 | 58.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 34 | $5,480 | $1,642 | 30.0% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 38 | 38 | $1,835 | $1,244 | 67.8% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 14 | 14 | $4,245 | $844.86 | 19.9% |
| 90471 | Administration of vaccine | Office | 2022 | 20 | 22 | $735.00 | $266.52 | 36.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 147 | 326 | $57,050 | $19,580 | 34.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 40 | 40 | $7,340 | $3,139 | 42.8% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 37 | 37 | $2,590 | $2,410 | 93.1% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2021 | 18 | 18 | $2,520 | $2,237 | 88.8% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2021 | 18 | 18 | $4,860 | $1,661 | 34.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 23 | $2,760 | $1,163 | 42.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 49 | 49 | $1,960 | $921.71 | 47.0% |
| G0009 | Administration of pneumococcal vaccine | Office | 2021 | 27 | 27 | $1,080 | $505.53 | 46.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 124 | 254 | $44,450 | $19,397 | 43.6% |
About Dr. Tracy Persily, D.O
Dr. Tracy Persily, D.O is a Family Medicine healthcare provider based in Willingboro, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2013. The National Provider Identifier (NPI) number assigned to this provider is 1568804912.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tracy Persily, D.O has received a total of $2,271 in payments from pharmaceutical and medical device companies, with $394.12 received in 2024. These payments were reported across 69 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($2,271).
As a Medicare-enrolled provider, Persily has provided services to 1,520 Medicare beneficiaries, totaling 2,151 services with total Medicare billing of $128,361. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Willingboro, NJ
- Active Since 07/26/2013
- Last Updated 10/08/2024
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1568804912
Products in Payments
- QULIPTA (Drug) $525.91
- Rybelsus (Drug) $279.31
- VRAYLAR (Drug) $174.51
- UBRELVY (Drug) $143.04
- Ozempic (Drug) $130.30
- Otezla (Drug) $124.99
- Repatha (Biological) $124.99
- RYBELSUS (Drug) $121.42
- Wegovy (Drug) $117.15
- MOUNJARO (Drug) $108.37
- EVENITY (Biological) $107.63
- Saxenda (Drug) $107.63
- Prolia (Biological) $31.11
- JARDIANCE (Drug) $30.76
- TRADJENTA (Drug) $21.47
- Androgel (Drug) $20.57
- Myrbetriq (Drug) $16.88
- QSYMIA (Drug) $15.39
- HUMULIN (Drug) $15.36
- PNEUMOVAX 23 (Biological) $13.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Willingboro
Dr. Christopher Salerno, Do, DO
Family Medicine — Payments: $1,257
Family Medicine $1,257
Dr. Marvin Weinar, M.d, M.D
Family Medicine — Payments: $958.84
Family Medicine $958.84
Dr. Camelia Vitoc, M.d, M.D
Family Medicine — Payments: $869.83
Family Medicine $869.83
Dr. Rocco Caveng, D.o, D.O
Family Medicine — Payments: $507.80
Family Medicine $507.80
Dr. Larisa Rozenberg, M.d, M.D
Family Medicine — Payments: $304.69
Family Medicine $304.69
Laurie Nemeth, Do, DO
Family Medicine — Payments: $246.25
Family Medicine $246.25